ScripBayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can
ScripAs a privately held and family-owned pharma firm, Boehringer Ingelheim has more freedom to dance to its own tune than most of its peers, but it has still been candid about the scale of its aspirations
ScripCRISPR Therapeutics is stepping outside its comfort zone by partnering up with Sirius Therapeutics to develop small interfering RNA (siRNA) therapies, particularly Sirius’s SRSD107 for thromboembolic
Pink SheetUse of J&J ‘s Darzalex Faspro (daratumumab and hyaluronidase-fihj) in smoldering multiple myeloma is almost certain to lead to over-treatment of some patients, the members of the US Food and Drug